FDA Cautions About Using PNC-27 as Cancer Treatment

The U.S. Food and Drug Administration (FDA) has issued a warning about the use of PNC-27, a product promoted and sold as a treatment or cure for cancer.¹

The FDA warning comes after a laboratory discovered the gram-negative bacteria Variovorax paradoxus in a PNC-27 solution sample for inhalation. Consumers who use a contaminated product of PNC-27 are at risk for developing potentially life-threatening infections. Vulnerable populations, such as young children, older individuals, pregnant women, and those with weakened immune systems, are at a higher risk for developing such infections.

There are no reported cases of illnesses or serious adverse events related to PNC-27.

PNC-27, which the website pnc27.com states is an important, non-toxic protein that can effectively treat any kind of cancer, has not been evaluated or approved as safe and effective to treat any disease, including any type of cancer, by the FDA.

The FDA recommends that patients who have used any PNC-27 product and have concerns should contact their health care provider as soon as possible and discuss their treatment options with a licensed clinician.

If clinicians become aware of adverse events related to the use of these products, they are encouraged to report such cases to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.

Reference

1. PNC-27 products: FDA warning – Do not use for treatment or cure for cancer. U.S. Food and Drug Administration website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm536763.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Publihed January 12, 2017. Accessed January 13, 2017.

This article originally appeared on Cancer Therapy Advisor